PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY | Market Cap | 144.78B -40.0% |
| Revenue (ttm) | 18.52B -60.3% |
| Net Income | -3.75B |
| EPS | -28.99 |
| Shares Out | 129.21M |
| PE Ratio | n/a |
| Forward PE | 10.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 955,300 |
| Average Volume | 876,625 |
| Open | 1,135.00 |
| Previous Close | 1,151.00 |
| Day's Range | 1,107.00 - 1,137.50 |
| 52-Week Range | 1,112.50 - 1,915.00 |
| Beta | 0.17 |
| RSI | 41.37 |
| Earnings Date | May 13, 2026 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery c... [Read more]
Financial Performance
Financial StatementsNews
PeptiDream announces initiation of Phase 1 clinical trial of AK1940
PeptiDream (PPTDF) announced that Asahi Kasei Therapeutics (AHKSY), its collaboration partner, has initiated a Phase 1 clinical trial of “AK1940”, a selective inhibitor of TNF receptor 1. AK1940 is a
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced ...
PeptiDream downgraded to Neutral from Buy at Citi
Citi downgraded PeptiDream (PPTDF) to Neutral from Buy with a price target of 1,600 yen, down from 2,700 yen. The firm says the company’s product out-licensing is taking longer than
PeptiDream Earnings Call Transcript: Q4 2025
2025 saw nearly double the clinical programs and strong radiopharmaceutical growth, though revenue missed forecasts due to delayed out-licensing. FY2026 guidance is conservative, with 6–12 new clinical programs expected and increased R&D investment, aiming for long-term revenue growth and pipeline expansion.
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Curium Group today announced that together with PeptiDream Inc. and PDRadiopharma Inc., the first patient has been dosed in the companies' registrational clin...
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
KAWASAKI, Japan--(BUSINESS WIRE)-- #IL17--PeptiDream is advancing the oral IL-17a/ IL-17F dual inhibitor peptide program into IND-enabling studies, while exploring strategic partnerships.
PeptiDream Transcript: Status Update
Significant R&D progress was made across radiopharmaceuticals and peptide therapeutics, with multiple programs advancing to clinical stages and robust growth in the radiopharmaceutical business. Major capital investments are underway to expand R&D and manufacturing capacity, supporting a strong outlook for continued pipeline expansion and innovation.
PeptiDream Earnings Call Transcript: Q4 2024
Record FY2024 results with revenue up 163% and net income up nearly 500% year-over-year, driven by expanded partnerships and pipeline progress. FY2025 guidance is conservative, with upside potential from major out-licensing deals and continued pipeline expansion.
PeptiDream Transcript: Investor Day 2024
The company is rapidly expanding its radiopharmaceutical and peptide therapeutic pipelines, launching new internal programs and advancing multiple partnered assets into clinical stages. Platform innovations in automation and AI are accelerating discovery and optimization, supporting a goal of at least one new internal program annually.
PeptiDream Earnings Call Transcript: Q2 2024
First half FY2024 revenue and profit targets were exceeded, driven by the expanded Novartis collaboration and strong cash inflows. The company is well-positioned for further growth, with additional deals and milestones expected in H2 2024 and a robust pipeline across both radiopharmaceutical and non-radiopharmaceutical segments.
PeptiDream downgraded to Hold from Buy at Jefferies
Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,300 yen, down from 1,600 yen. The downgrade reflects eliminating the estimated contribution from a
PeptiDream upgraded to Buy from Hold at Jefferies
Jefferies upgraded PeptiDream to Buy from Hold with a price target of 1,600 yen, down from 1,900 yen. The analyst says the company seems likely to book a strong Q3
PeptiDream downgraded to Hold from Buy at Jefferies
Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,900 yen, down from 2,200 yen. The analyst has become more optimistic about the company’s
PeptiDream downgraded to Hold from Buy at Jefferies
Jefferies downgraded PeptiDream to Hold from Buy with a price target of 1,900 yen, down from 2,200 yen. The firm has become “more optimistic” about radiopharma revenues, but “less optimistic”